A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/17/2002	US20020150953 Detecting modulators of muscle protein activity; obtain mixture of calcineurin and muscle protein, monitor binding, incubate with modulator, monitor adjustment in binding activity compare to control
10/17/2002	US20020150946 Mammalian tolloid-like gene and protein
10/17/2002	US20020150924 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of prostate cancer
10/17/2002	US20020150922 Compositions and methods for the therapy and diagnosis of colon cancer
10/17/2002	US20020150914 Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
10/17/2002	US20020150910 33410, a novel human carboxylesterase family member and uses thereof
10/17/2002	US20020150901 Novel nucleic acids, polypeptides, methods of making, and uses thereof
10/17/2002	US20020150898 Novel nucleic acids and polypeptides
10/17/2002	US20020150888 Methods of screening for modulators of HIV infection
10/17/2002	US20020150881 Recovering nucleotide sequences coding preferential protein; obtain phage coding preferential protein, express protein, separate phage displaying binding domain, recover phage displaying chimeric binding protein on surface
10/17/2002	US20020150629 Enhancing absorption; mixture of zinc compound and dipeptide
10/17/2002	US20020150603 Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
10/17/2002	US20020150591 Amplification nucleic acids
10/17/2002	US20020150588 Hybrid polypeptides; diagnosis, monitoring cancer
10/17/2002	US20020150583 Tumor necrosis factor receptors 6alpha & 6beta
10/17/2002	US20020150582 Administering tumor necrosis factor antigen
10/17/2002	US20020150581 Compositions and methods for the therapy and diagnosis of breast cancer
10/17/2002	US20020150580 Administering genetic engineered antibody; binding to antigen; rheumatic diseases, skin disorders, autoimmune disease
10/17/2002	US20020150577 Transforming growth factor; transgenic animal; increas ratios of muscle mass
10/17/2002	US20020150568 Stimulation, controlling cell differentiation
10/17/2002	US20020150567 Novel grb2 associating polypeptides and nucleic acids encoding therefor
10/17/2002	US20020150566 Administering hybrid Ras proteins; anticancer agents
10/17/2002	US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002	US20020150564 Wound healing compositions and methods using tropoelastin and lysyl oxidase
10/17/2002	US20020150563 Hybrid polynucleotide; antibodies
10/17/2002	US20020150559 Binding of human antigens
10/17/2002	US20020150558 Immobilization; viricides
10/17/2002	US20020150555 Interleukins; osteoporosis therapy
10/17/2002	US20020150554 Chicken interleukin-15 and uses thereof
10/17/2002	US20020150553 Compositions containing C-terminal polypeptides of angiogenic chemokines and methods of use
10/17/2002	US20020150552 Compositions comprising mixtures of therapeutic proteins and methods of producing the same
10/17/2002	US20020150551 Protease surface treatment
10/17/2002	US20020150547 Blend of plant extracts and biopolymer
10/17/2002	US20020150541 Mixture of human interferons; viricides; anticancer agents; antiinflammatory agents;
10/17/2002	US20020150534 Tumor necrosis factor-gamma
10/17/2002	CA2827167A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	CA2762966A1 Hsa-free formulations of interferon-beta
10/17/2002	CA2606839A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	CA2479780A1 Antisense calpain nucleotides and uses thereof
10/17/2002	CA2446886A1 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002	CA2443813A1 Method for identification of proteins from intracellular bacteria
10/17/2002	CA2443694A1 Anti-cd19 immunotoxins
10/17/2002	CA2443641A1 Antisense modulation of phospholipid scramblase i expresion
10/17/2002	CA2443378A1 Methods of screening and using inhibitors of angiogenesis
10/17/2002	CA2443334A1 Protein modification and maintenance molecules
10/17/2002	CA2443319A1 Novel human kinase and polynucleotides encoding the same
10/17/2002	CA2443293A1 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes
10/17/2002	CA2443277A1 Interferon gamma polypeptide variants
10/17/2002	CA2443223A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
10/17/2002	CA2443207A1 Process for producing trunkamide a compounds
10/17/2002	CA2443085A1 Somatostatin agonists
10/17/2002	CA2443025A1 Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
10/17/2002	CA2443018A1 Papaine containing pharmaceutical formulation resp. its use
10/17/2002	CA2442957A1 Renal cell carcinoma tumor markers
10/17/2002	CA2442923A1 Polysubstituted polycarboxylic phosphoamide biopolymers, methods for their production and uses of compositions derived therefrom
10/17/2002	CA2442739A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
10/17/2002	CA2442685A1 Estrogen receptor-related receptor alpha (err.alpha.) and cartilage formation
10/17/2002	CA2442386A1 Epitope sequences
10/17/2002	CA2442382A1 Methods for using annexin for detecting cell death in vivo and treating associated conditions
10/17/2002	CA2442315A1 Glycosaminoglycan/collagen complexes and use thereof
10/17/2002	CA2442092A1 Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
10/17/2002	CA2441628A1 Alpha-galactosidase as food-grade genetic marker
10/17/2002	CA2441538A1 Stimulation of osteogenesis using rank ligand fusion proteins
10/17/2002	CA2441442A1 Conjugate of hydroxyalkyl starch and an active agent
10/17/2002	CA2440724A1 Pyrazolopyrimidines as therapeutic agents
10/17/2002	CA2440219A1 Proteins, polynucleotides encoding them and methods of using the same
10/17/2002	CA2440196A1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease
10/17/2002	CA2439503A1 Recombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitor
10/17/2002	CA2435528A1 Novel polypeptides and nucleic acids encoded thereby
10/17/2002	CA2434456A1 Yeast genes that affect viral replication
10/17/2002	CA2429376A1 Mitogenic oxygenase regulators
10/16/2002	EP1249492A2 Antibodies against an adrenergic receptor
10/16/2002	EP1249491A2 Human very long chain acyl-CoA synthase (VLCAS)-like protein and nucleic acids encoding it
10/16/2002	EP1249244A1 Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
10/16/2002	EP1249229A2 Sustained delivery of an active agent using an implantable system
10/16/2002	EP1248858A1 Antisense modulation of caspase 8 expression
10/16/2002	EP1248849A1 Obg3 globular head and uses thereof for decreasing body mass
10/16/2002	EP1248848A1 Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides
10/16/2002	EP1248847A1 Irak-4: compositions and methods of use
10/16/2002	EP1248846A2 Human kinase protein and polynucleotides encoding the same
10/16/2002	EP1248844A1 Analogs of human basic fibroblast growth factor
10/16/2002	EP1248843A2 Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses
10/16/2002	EP1248837A2 Angiotensin converting enzyme homolog and its use
10/16/2002	EP1248836A2 Hybrid cells obtainable from antigen presenting cells
10/16/2002	EP1248813A2 Antisense antibacterial cell division composition and method
10/16/2002	EP1248803A2 Nogo receptor-mediated blockade of axonal growth
10/16/2002	EP1248802A2 Soluble ctla4 mutant molecules and uses thereof
10/16/2002	EP1248801A1 Human polynucleotides, polypeptides, and antibodies
10/16/2002	EP1248800A2 Compositions and methods for therapy and diagnosis of breast cancer
10/16/2002	EP1248796A1 Process for the purification of antothrombin-iii
10/16/2002	EP1248795A1 Antisense modulation of macrophage migration inhibitory factor expression
10/16/2002	EP1248794A1 Antisense modulation of smad7 expression
10/16/2002	EP1248793A1 Polynucleotides for inhibiting metastasis and tumor cell growth
10/16/2002	EP1248792A1 Antisense modulation of peroxisome proliferator-activated receptor gamma expression
10/16/2002	EP1248791A1 Antisense modulation of caspase 3 expression
10/16/2002	EP1248654A2 Intra-tumoral administration of il-12 encoding nucleic acid molecules
10/16/2002	EP1248645A1 Novel chimeric proteins and methods for using the same
10/16/2002	EP1248643A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
10/16/2002	EP1248642A1 Vegf-d/vegf-c/vegf peptidomimetic inhibitor
10/16/2002	EP1248641A1 Use of emap ii receptor antagonist composition for treating pulmonary hypertension

1 ... 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 ... 3163